This site is intended for healthcare professionals
Drug news

FDA approves Rasuvo SC for Rheumatoid Arthritis - Medac Pharma

Read time: 1 mins
Last updated:16th Jul 2014
Published:16th Jul 2014
Source: Pharmawand

The FDA has approved Rasuvo (subcutaneous injectable methotrexate), from Medac Pharma, delivered in an auto-injector for Rheumatoid Arthritis (RA), polyarticular-course juvenile idiopathic Arthritis (pJIA) and Psoriasis. Rasuvo will be available in 10 dosage strengths, ranging from 7.5 mg to 30 mg in 2.5 mg increments and will be launched in the US.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights